MK-2010: Administered as an intravenous (IV) infusion.
Pembrolizumab: Administered intravenously as 400 mg every 6 weeks.
5-Fluorouracil: Administered intravenously per approved product label.
Leucovorin or Levoleucovorin: Administered intravenously per approved product label.
Oxaliplatin: Administered intravenously per approved product label.
Belzutifan: Administered orally as 120 mg daily.
Gemcitabine: Administered intravenously per approved product label.
Cisplatin: Administered intravenously per approved product label.
Carboplatin: Administered intravenously per approved product label.
Paclitaxel: Administered intravenously per approved product label.
Nab-paclitaxel: Administered intravenously per approved product label.
Pemetrexed: Administered intravenously per approved product label.
Epinephrine: Administered per approved product label as rescue medication.
Study summary
Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery.
In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer.
The goals of this trial are to learn:
* About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems.
* How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Has radiographically measurable disease per protocol
* If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption
* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV
* Has adequate organ function per protocol
Exclusion Criteria:
* Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV
* Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
* Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
* Has a history of confirmed inflammatory bowel disease
* Has a serious active nonhealing wound, ulcer, and/or bone fracture
* Has a history of myocarditis or cardiomyopathy
* Has a history of or current severe cardiovascular and cerebrovascular diseases
* Is currently receiving any anticoagulants
* Has a diagnosis of immunodeficiency
* Has a known additional malignancy that is progressing or required active treatment within the past 3 years
* Has known active central nervous system metastases and/or carcinomatous meningitis
* Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed)
* Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD
* Has a history of stem cell/solid organ transplant
* Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
Primary outcome measure(s)
Number of Participants with Adverse Events (AEs) — Up to approximately 24 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Discontinue Study Treatment Due to an AE — Up to approximately 24 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Experience Dose-Limiting Toxicity (DLT) — Up to approximately 28 days DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next dose.
Objective Response Rate (ORR) — Up to approximately 24 months ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.
Trial sites (4)
Facility
City
Region
Status
START Astera, LLC ( Site 0220)
East Brunswick
New Jersey
Taylor Cancer Research Center ( Site 9500)
Maumee
Ohio
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
